A detailed reference for eye care professionals on evidence-based uses of amniotic membrane across anterior segment pathology.
Dry eye disease affects an estimated 16 million Americans and represents one of the most common reasons patients seek ophthalmic care. For patients with moderate-to-severe DED who have failed conventional topical therapies, amniotic membrane offers a meaningful therapeutic advance.
Self-retained amniotic membrane devices are placed on the ocular surface in-office under topical anesthesia and worn for 5–7 days. The membrane's sustained release of anti-inflammatory mediators — including IL-1 receptor antagonist and TSP-1 — directly targets the inflammatory cascade underlying DED.
Clinical studies have demonstrated statistically significant improvements in corneal staining, conjunctival staining, TBUT, and patient-reported symptom scores following treatment cycles. Many patients experience benefits lasting weeks to months after a single treatment.
Key indication: Moderate-to-severe DED refractory to artificial tears, anti-inflammatories (cyclosporine, lifitegrast), or punctal occlusion.
Persistent epithelial defects (PEDs) are defined by failure of corneal epithelial healing beyond 2 weeks despite standard management. Left untreated, PEDs can progress to stromal melting, perforation, and permanent vision loss.
Amniotic membrane is a well-established intervention for PEDs regardless of etiology. Applied stroma-side down to the defect, it provides a basement membrane template that stimulates limbal stem cell migration and epithelial proliferation. Simultaneously, growth factors including EGF and KGF promote keratinocyte migration and differentiation.
Amniotic membrane is effective across a range of etiologies:
Loss of corneal innervation impairs epithelial integrity and healing. Amniotic membrane provides structural and trophic support independent of neural signaling, making it particularly valuable in neurotrophic ulcers.
Following resolution of active bacterial, fungal, or viral infection, amniotic membrane accelerates re-epithelialization and reduces the risk of fibrotic scarring that limits final visual acuity.
In patients with lagophthalmos or reduced Bell's reflex, amniotic membrane serves as a biological bandage, protecting the cornea and promoting healing until the underlying lid issue can be addressed.
Ocular chemical burns — particularly alkali injuries — represent ophthalmic emergencies with potentially devastating consequences, including limbal stem cell deficiency (LSCD), corneal opacification, and total blindness.
Amniotic membrane applied within the first 24–48 hours of injury has been shown to significantly improve visual outcomes by:
For grade III–IV chemical burns (Dua classification), multilayered amniotic membrane application — securing multiple overlapping layers to the entire ocular surface — is recommended to maximize coverage and biological activity.
Timing is critical. Research suggests that amniotic membrane application within the first 24 hours of chemical injury significantly reduces the risk of limbal stem cell deficiency and the need for subsequent stem cell transplantation.
Pterygium surgery carries a significant recurrence risk — up to 40–80% with bare sclera excision alone. Amniotic membrane transplantation (AMT) following excision provides an alternative or adjunct to conjunctival autograft (CAG), with several clinical and practical advantages.
Amniotic membrane is routinely incorporated into anterior segment surgical workflows to support healing and minimize complications in high-risk cases:
Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN) are life-threatening mucocutaneous reactions that cause severe ocular surface inflammation with risk of permanent vision loss. Ocular involvement occurs in up to 80% of SJS/TEN cases.
The acute phase of SJS is characterized by pseudomembrane formation, conjunctival sloughing, and ulceration. Without intervention, this progresses to cicatricial conjunctivitis, trichiasis, symblepharon, and LSCD.
Amniotic membrane applied during the acute phase of SJS — ideally within the first 2–3 weeks — has been shown to dramatically reduce long-term ocular sequelae. Symblepharon ring-retained AM covering the entire ocular surface is the preferred approach.
Multiple published case series and prospective studies support early AM application as the standard of care during SJS acute phase, particularly in patients with grade 2+ ocular involvement (Sotozono grading system).